John H.TuMD

Dermatology • Rochester, NY

Physician

Join to view full profile

Dr. Tu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tu's full profile

Already have an account?

Office
100 White Spruce Blvd
Suite 3
Rochester, NY 14623
Phone+1 585-272-0700

Fax+1 585-272-8356

Education & Training

University of Rochester Institute of OpticsMS, Optics, 2001 - 2003
Massachusetts General HospitalPost-Doctoral Fellowship, 1998 - 2000
Washington University/B-JH/SLCH ConsortiumResidency, Dermatology, 1995 - 1998
UCLA David Geffen School of Medicine/UCLA Medical CenterInternship, Internal Medicine, 1994 - 1995
Albert Einstein College of MedicineClass of 1994

Certifications & Licensure

NY State Medical License 2001 - 2026
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Fellow (FAAD) American Academy of Dermatology
Fellow (FASDS) American Society for Dermatologic Surgery

Clinical Trials

VPD-737 for Treatment of Chronic Pruritus Start of enrollment: 2013 Oct 15
Completed
Phase 2
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) Start of enrollment: 2014 Jun 16
Completed
Phase 3
A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis Start of enrollment: 2014 May 01
Completed
Phase 2
A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris Start of enrollment: 2015 Apr 01
Completed
Phase 2
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Aug 01
Completed
Phase 3
Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis Start of enrollment: 2015 Aug 01
Completed
Phase 3
Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis Start of enrollment: 2015 Aug 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

1 citations
Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1.
Kavita Y Sarin, Mark Bradshaw, Chris O'Mara, Jahanbanoo Shahryari, John Kincaid
Science Advances. 2024-05-03
147 citations
Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.
Kristian Reich, Kim A. Papp, Robert Matheson, John H. Tu, Robert Bissonnette
Experimental Dermatology. 2015-07-01
27 citations
Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes.
Matthias Augustin, John H. Tu, Kim Mark Knudsen, Sandra Erntoft, Thomas Larsson
Journal of the American Academy of Dermatology. 2015-05-01

Professional Memberships

American Academy of Dermatology - AAD
Fellow
American Society for Dermatologic Surgery - ASDS
Fellow

Other Languages

Chinese (Mandarin)

External Links

Officehttps://www.dermrochester.com/